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Over the past ten years it has been increasingly recognized
that immune complex nephritides, characterized by the accu-
mulation of granular immune deposits in renal structures, may
not only be the consequence of deposition of circulating im-
mune complexes but also of antigen-antibody complexes aggre-
gated locally or formed in situ [1]. One of the sites at which
antibodies may interact locally with antigens in the kidney is at
the surface of renal cells [1, 2]. There is an abundance of
antigens on cells: part of them are intrinsic plasma membrane
proteins, while others may be present because they are secre-
tion products or they have been "planted" on the cell surface
for immunological or physico-chemical reasons. In this article
renal lesions that may arise from the binding of antibodies with
these various kinds of cell surface antigens will be reviewed.
Most of our insights come from animal models of renal disease.
In the closing section the potential impact of data derived from
experimental pathology on our concepts of human nephrop-
athies will be evaluated.
Plasma membrane antigens
At the core of the membrane surrounding the plasm of cells is
a bilayer of lipid molecules. A key property of this lipid bilayer
is that, while being a stable planar structure, it possesses
fluidity: proteins and lipids floating in the plasma membrane are
able to move and diffuse laterally in any direction. The many
kinds of proteins inserted into the plasma membrane function as
receptors for a variety of ligands in the extracellular medium,
form specialized transmembrane pumps or channels, convey a
negative charge to the cell surface, or serve other not always
yet defined physiological roles [2—4].
A few substances such as water and dissolved gasses may
diffuse across the plasma membrane. For other substances in
the extracellular milieu there are two principal routes into cells.
The first is represented by the pumps and channels that trans-
port ions and small water-soluble molecules such as amino
acids and sugars into the cytoplasm. The second route, allowing
large molecules and particulate matter to enter the cell, is by
means of endocytosis. Three types of endocytosis are dis-
cerned. Very large particles may be brought into cells by
phagocytosis. Fluid with whatever molecules happen to be in it
may reach the cytoplasm by the process of pinocytosis. The
third type, receptor-mediated endocytosis, involves the binding
of ligands to their corresponding transmembrane (amphipathic)
protein receptors and is, in contrast to phagocytosis and pi-
© 1989 by the International Society of Nephrology
nocytosis, very specific [3, 4]. A great variety of receptors has
been described including specific receptors for transport pro-
teins that deliver nutrients to cells (such as, low density
lipoprotein, transferrin, ferritin), non-transport plasma proteins
(such as, a-2 macroglobulin, immune complexes), cytokines
(such as, protein growth factors, interleukins), hormones (such
as, insulin, luteinizing hormone), certain enzymes, toxins and
lectins, and viruses [3—5]. Receptors (cell surface Ig and MHC
antigens) also play a pivotal role in the immune response [3, 6—
8]. The receptor makeup is different from one cell type to
another. Receptor-mediated endocytosis is initiated by ligands
joining their respective receptors. If not already inside coated
pits, receptor-ligand complexes move laterally to cluster in
these specialized plasma membrane structures. Coated pits,
found on all cells except red blood cells, are so named because
these plasma membrane indentations are covered at the cyto-
plasmic side by a furry coat mainly composed of a characteristic
protein, clathrin [9]. Coated pits are short-lived as they, with
different receptor-ligand complexes inside, in an energy-depen-
dent process, pinch off the plasma membrane to form intracel-
lular coated vesicles. Once inside the cell, the vesicles shed
their clathrin coat, fuse with one another and become part of the
endosomal compartment, which is composed of a network of
vesicles and tubules [3, 4, 10]. Helped by a low pH in the
endosomal compartment, many types of ligands disconnect
from their receptors to be dispatched to lysosomes where they
are degraded. By contrast, the membrane lipids together with
receptors rejoin the plasma membrane in a process of exocyto-
sis [3, 4, 10]. One of the alternative final destinations of ligands
is the release from the cell at a site other than that of entrance.
This has been shown for example for maternal IgG in newborn
rats and for secretory IgA [11]. The process of endocytosis then
entails a rapid sequence of intricate and complex rearrange-
ments and fusion of membranes with some types of cells
internalizing as much as half of the plasma membrane per hour.
Whereas most types of receptors are internalized in coated pits
only, a notable exception is the insulin receptor, which may
also be endocytosed, in a non-concentrative manner, in pinocy-
totic invaginations [12]. One might expect that lack of func-
tional receptors could lead to disease. In fact this has been
convincingly demonstrated in patients with familial hypercho-
lesterolemia [3, 10].
While most natural ligands will not crosslink their plasma
membrane receptors, such a situation can conveniently be
created and studied in vitro by using antibodies against such
diverse receptors as surface Ig, thymus leukemia antigen,
measles hemagglutinating antigen, and Fc and C3b/C4b recep-
954
Brentjens and Andres: Antibody interaction with antigens 955
tors [2, 5, 13—171. The rapid succession of changes following the
binding of antibodies to these receptors may be divided into
three phases [5, 131. First, the receptors cluster in small patches
that by diffusing laterally fuse into larger ones (micro-immune
complex-precipitates). This is a passive process requiring only
divalency of the antibody and a temperature above 4°C. In the
second phase, the patches accumulate in a cap at one pole of the
cell. This antibody-induced receptor redistribution is associated
with increased cell motility. With the leading, "ruffled" edge of
the motile cell free from receptor-antibody complexes, these
complexes are concentrated in the cap at the rear of the cell
(uropod). This phase is energy-dependent. Thus capping is
prevented not only by low temperature but also by inhibitors of
the respiratory chain or of glycolysis. Another requirement for
capping is an intact, functional cytoskeleton. The cytoskeleton
("the muscles and bones of the cell") is composed of microfil-
aments (also referred to as actin filaments), intermediate fila-
ments, microtubules, and nuclear structures [181. Although the
precise mechanism is unknown, crosslinked transmembranous
proteins connect with the microfilaments and these structures
together with myosin can be seen to aggregate in the cytoplasm
underneath the caps [13, 19, 20]. Further support for the
participation of the cytoskeleton comes from the observation
that drugs that interfere with cytoskeletal function (cytocha-
lasin B, phenothiazines) also interfere with cap formation [21,
22]. In the third phase the caps are removed by endocytosis
and, in some instances at least, by shedding, leaving the cell
surface devoid of the receptors involved. This phenomenon has
been called "antigenic modulation", as antibodies will no
longer find their targets on the plasma membrane [5, 14]. In the
absence of further exposure of the cells to specific antibodies,
the surface receptors are most of the time reexpressed. All
three phases of the antibody-mediated receptor redistribution
take place in a matter of minutes.
Plasma membrane antigens that upon crosslinking do not
become anchored to the cytoskeleton, as for example Thy-i and
MHC Class I antigens and certain glycolipids still can be
induced to cap [6, 13, 17, 23—26]. This capping reaction called
"passive" to contrast with the active process described above,
has much slower kinetics, may require a double layer of ligands,
and is not inhibited by cytoskeleton-suppressing drugs [13, 17].
It may be that in passive capping, directional plasma membrane
recycling is a driving force [261. This latter mechanism may also
be invoked to explain some degree of redistribution of surface
antigens occurring spontaneously in moving cells or in cells
forming a uropod [26, 27].
Several studies have addressed antibody-mediated plasma
membrane antigen redistribution in vivo [reviewed in 51. In one
such study [28] for four days rabbits received goat antibodies
directed against angiotensin converting enzyme (ACE), a trans-
membrane protein especially expressed on the surface of alve-
olar endothelial cells [29]. Due to pulmonary edema, many
animals did not survive the first day of injection. Immunofiuo-
rescence microscopy revealed granular deposits (patches) of
goat IgG, rabbit C3, and ACE along the alveolar capillary
endothelium. The granular distribution of ACE after interaction
in vivo with antibody contrasted with the even, linear expres-
sion of the enzyme on the surface of the alveolar endothelium
observed in normal lung. Rabbits surviving the first day toler-
ated subsequent administration of anti-ACE antibodies without
clinically apparent ill effects. The change in the response to
antibody injection was explained by the disappearance of ACE
from the lung after continued interaction with specific antibody.
The "immunological enzymectomy" of ACE from the lung was
interpreted as an example of antigenic modulation. Within 24
hours of discontinuation of antibody administration, ACE was
detectable again in the lung.
As stated before, the capped receptor-antibody complexes
are removed by endocytosis [13, 301. To what extent shedding
of the complexes contributes to the removal process is in most
instances unknown [5, 31]. In at least one system, involving
oocytes, there is convincing evidence that shedding does occur
[32]. The first description of the coated pit system and the
correct interpretation of its function came from studies on
insect eggs [33]. It was recognized that yolk proteins produced
elsewhere enter the oocyte via coated pit-directed endocytosis.
In rabbit oocytes, ACE appears to be present as a surface
protein [34]. The expression of ACE is diffuse and not limited to
coated pits. Binding in vivo of goat anti-ACE antibodies to ACE
induces redistribution of ACE followed by the appearance in
the zona pellucida of morphologically recognizable aggregates
composed of goat IgG, rabbit C3, and ACE. The shedding and
aggregation of immune complexes seems to take place prefer-
entially at the level of the oocyte microvilli, a situation resem-
bling that observed for crosslinked Ig on B-cells [27]. Small
round profiles noted around and in the immune deposits may be
oolemma-derived [32].
A physiological role for crosslinkage of plasma membrane
proteins is illustrated by B-cell differentiation, proliferation,
and antibody secretion subsequent to binding of polyvalent
antigens to surface Ig [13, 35, 36]. Plasma membrane redistri-
bution and antigenic modulation may also be important for
understanding pathological conditions, among them the renal
diseases discussed below in this section, certain autoimmune
diseases, and chronic viral infections [5, 15, 37]. Lastly, anti-
genic modulation should be taken into account in therapeutic
modalities involving the use of antibodies against cell surface
antigens [5].
Glomerular visceral epithelial cells
1. Heymann glomerulonephritis. a. Introduction. In 1959
Heymann et al [38] demonstrated that active immunization of
rats with whole rat kidney homogenates incorporated into
Freund's adjuvants induces a nephrotic syndrome. Proteinuria
results from abnormal deposits of immunoglobulins and com-
plement in the glomerular capillary walls, corresponding to
deposits of foreign material at the epithelial side of the base-
ment membrane [39]. These findings are similar to those seen in
the glomeruli of patients with idiopathic membranous glomeru-
lonephritis, and Heymann glomerulonephritis has been ac-
cepted as a model for the human disease. Edgington, Glassock
and Dixon [40] and Grupe and Kaplan [41] demonstrated that
the antigen is localized in a membrane preparation (FxIA)
derived from rat proximal convoluted tubules. A more purified
and nephritogenic fraction was called RTEa5 [42]. Miettinen et
al used lectin affinity chromatography to isolate eight glycopep-
tides. This was the first indication that the antigen is a glyco-
protein [43]. Because antibodies eluted from glomeruli of rats
with Heymann glomerulonephritis react with glonieruli of ne-
phritic, but not of normal rats, the disease was considered as
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due to a local deposition of immune complexes formed in the
circulation by a tubular brush border antigen and corresponding
antibody [421. This interpretation was strengthened by the first
descriptions of passive Heymann glomerulonephritis. When it
was shown that rats injected with heterologous [44, 45] or
autologous [46] brush border antibodies rapidly develop Hey-
mann glomerulonephntis, the lesions were again ascribed to
circulating immune complexes because the available immuno-
histological techniques did not detect the binding of antibody to
normal glomeruli in tissue sections. The challenge to this basic
concept originated from the studies of van Damme et al [47] and
Couser et al [48] who, using cx vivo or isolated perfused
kidneys, showed that the anti-Fx1A antibodies fix directly to
glomeruli. The results indicated that the antigen is present in the
glomerular capillary wall and is similar enough to that on the
tubular brush border to be recognized by the antibody. The
visualization of the glomerular antigen in vitro was more
difficult to achieve. Bertani et al [491 described a weak binding
of heterologous affinity-purified FxlA antibody to glomeruli in
tissue sections. Similar results were reported by Neale et a!
[50], who used antibodies eluted from the kidneys of rats with
Heymann glomerulonephritis. However, the definitive evidence
that the most relevant antigen of Heymann glomerulonephritis
is expressed at the surface of glomerular visceral epithelial
cells, its partial biochemical characterization, and the demon-
stration of its nephritogenicity were provided by Ketjaschki and
Farquhar [51, 52]. Their results stimulated the search for other
structural nephritogenic antigens in the rat, in other laboratory
animals and in man. Moreover, attention was focused on the
pathogenic role of Heymann antibodies in the epithelial cells of
proximal tubules and of the yolk sac.
b. Antigens. The development of monoclonal antibody tech-
nology and the application of plasma membrane biochemistry to
the study of glomerular diseases allowed to identify several
antigens at the surface of tubular and glomerular cells. The
membrane composition of the epithelial cells in the initial (S1
and S2) segments of the proximal tubule is characterized by
distinct microdomains [53]. Maltase is concentrated in the
microvilli and similarly distributed are the 130 and 94 gamma-
glutamyl transpeptidases and the 70-90 kD dipeptidyl peptidase
IV. The latter is also present in the Golgi apparatus, in
intracytoplasmic vacuoles and on the basolateral membranes
[54]. gp330 is a glycoprotein of 330 kD which was isolated from
purified rat brush border fractions, solubilized in detergent,
iodinated and subjected to precipitation with IgG eluted from
glomeruli of rats with Heymann glomerulonephritis. The pro-
tein was subsequently purified by gel filtration and lentil lectin
affinity chromatography [51]. gp330 is concentrated in clathrin-
coated apical invaginations at the base of the microvilli [53]. In
normal rats gp330 is not internalized during endocytosis,
whereas, in rats treated with sodium maleate, which reduces
protein reabsorption, it is internalized in newly formed apical
vacuoles. The lysosomal membrane glycoprotein, lgpl20, is
restricted to lysosomes, whereas endosomes do not contain any
of the antigens previously mentioned [55]. Since Heymann
antibodies are present in the glomerular filtrate of protcinuric
rats it is not surprising that tubular injury may develop (see
section Tubular cells: Heymann nephritis).
The best characterized glomerular antigen is gp330. By
immunohistochemistry gp330 has been demonstrated in the
Golgi elements, in the endoplasmic reticulum, in the multive-
sicular bodies and in the coated pits of visceral epithelial cells.
Treatment of tissue with neuraminidase exposes diffuse reac-
tive sites on the epithelial plasmamembrane. This pattern of
localization suggests that gp330 is synthetized by the po-
docytes, transported to the Golgi where terminal glycosylation
occurs [56], ferried to the cell membrane via secretory vesicles,
and concentrated into the coated pits [52, 54]. However, it is
difficult is to explain the presence of gp330 in multivesicular
bodies which have been shown to discharge gp330 into the
urinary space [56]. Multivesicular bodies are prelysosomal
structures involved in uptake of both intracellular [57] and
circulating proteins [58]. It has been proposed that gp330 may
be transferred directly from the Golgi to the multivesicular
bodies, or that cell surface gp330 may be internalized into
multivesicular bodies, or that gp330 produced elsewhere may
bind to coated pits, taken up by endocytosis, and subsequently
delivered to the multivesicular bodies [59]. The second and the
third hypothesis are consistent with a bidirectional cellular
transport of gp330. The pattern of localization at the cell surface
suggests that this glycoprotein may be a receptor or a ligand [52,
59]. Recent studies report that monoclonal antibodies to gp330
block the adherence of tubular epithelial cells to the basement
membrane matrix. Further, gi330 would selectively bind to
fibronectin. Taken together these results are interpreted as
evidence that gp330 is a fibronectin receptor [60]. In other
absorptive epithelia (intestine, epididymis, and embryonic vis-
ceral yolk sac) gp330 is also localized in coated pits, Golgi,
endoplasmic reticulum and multivesicular bodies [61].
The discovery of gp330 was a stimulus for studies designed to
extend the mapping of cell surface antigens in the glomerular
capillary wall. Other antigens, isolated from the brush border
and shared by glomerular cells were described. It is not certain
that all the preparations represent single glycoproteins. The
data concerning gp600, for example, suggest that it may be a
labile complex of five loosely associated polypeptides, possibly
a precursor of gp330 [62]. Another antigen of 108 kD was
characterized as a monomer of dipeptidyl peptidase IV [63].
Several investigators [64—671 isolated, alone or in the associa-
tion with gp330, a 70-90 kD protein present in transport epithe-
ha, in the glomerular endothelium [65—67], and in the majority
of normal lymphocytes [68]. gp7O-90 is dipeptidyl peptidase IV
[67], one of the major hydrolases of the renal brush border and
of the gut, probably responsible for the hydrolysis of physio-
logically active peptides. Besides, dipeptidyl peptidase IV
seems to be involved in the fibronectin-mediated spreading of
cells on basement membrane matrices [69]. A 140 kD molecule,
corresponding to the highly negatively charged coat (polyanion)
of glomerular cells has been isolated and called "podocalyxin"
[70]. Podocalyxin is evenly distributed on the podocyte plas-
malemmal surface [70] but not at the "soles" of the foot
processes [71]. Moreover, it is unevenly distributed on the
luminal membrane domain of many endothehia, including the
glomerular endothehium [72]. Another glycoprotein, with dcc-
trophoretic mobility (130 kD) lower than that of podocalyxin
was detected by immunohistochemica! methods at the base of
the foot processes in tissue treated with neuraminidase [73].
Heparan sulphate proteoglycans, different from those present in
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the laminae rarae of the glomerular basement membrane, have
been shown in the glycocalyx of glomerular epithelial and
endothelial cells [74]. A similar localization is characteristic of
another 62 kD protein called "podoendin" [75].
c. Antibodies. The nephritogenic potential of antibodies elic-
ited by immunization with each separate component of the
tubular brush border has not been established with equal rigor.
The best characterized antibodies are those reactive with gp330
[51]. They are consistently eluted from glomeruli of nephritic
rats [51, 761, induce subepithelial immune deposits after passive
transfer [59, 76], and are present in the sera of rats immunized
with Edgington' s original brush border preparation [761. Active
immunization with gp330 induces subepithelial immune depos-
its while proteinuria (200-400 mg/24 hours) is observed in a few
rats [76]. Since immunization with FxlA is associated with
glomerular lesions and proteinuria more severe than those
occurring after immunization with gp330 [64, 671, it was sug-
gested that crude antigenic preparations stimulate synthesis of
multiple nephritogenic antibodies. The most likely candidates
to enhance the effect of antibodies to gp330 are antibodies to
dipeptidyl peptidase IV (gp7O-90), an antigen mainly expressed
at the surface of glomerular endothelial cells [54, 66, 671. First,
after injection, or perfusion of rat kidney with rabbit antiserum
to anti-rat FxIA, which contains antibodies to gp7O-90, fine
granular deposits of rabbit IgG are seen in the glomerular
endothelium. The deposits rapidly disappear and, after 8 hours,
become detectable at the epithelial side of the basement mem-
brane [77]. The short-lived, complement-fixing, endothelial
interaction may contribute to increase the glomerular perme-
ability, thus facilitating the access of anti-gp330 antibodies to
the surface of epithelial cells [67]. The hypothesis that anti-
endothelial antibody may contribute to the pathogenesis of
classical Heymann glomerulonephritis is supported by the
observation that when rabbits are injected with antibodies to
ACE, immune complexes are initially formed at the level of the
glomerular endothelium and subsequently migrate across the
basement membrane and aggregate at its epithelial side [78] (see
section Glomerular endothelial cells. 1. Lesions mediated by
anti-ACE antibodies). Second, subepithelial deposits are ob-
served in rat kidneys perfused ex vivo with polyclonal antibod-
ies reactive with the 90 kD components of Fx1A [791, and
transient subepithelial deposits are seen in kidneys of rats
injected with an anti-90 kD monoclonal antibody reactive with
the brush border and with the plasma membrane of glomerular
endothelial and epithelial cells [67, 801. Third, anti-gp9O anti-
bodies can be eluted from glomeruli of nephritic rats [64, 65].
Fourth, anti-gp7O-90 antibodies induce Heymann glomerulone-
phritis in mice [81, 821 and transient subepithelial immune
deposits in rabbits [67]. Other antibodies with nephritogenic
potential are those reactive with laminin, fibronectin, and type
IV collagen. For reasons that are presently unknown, immuni-
zation with Fx1A elicits the synthesis of antibodies which bind
to the glomerular basement membrane with a linear pattern and
fix complement. Furthermore, injection of anti-FxIA antibodies
absorbed with glomerular basement membrane fails to induce
formation of subepithelial deposits as large as those seen in rats
injected with the unabsorbed antiserum [83].
Not much is known about the genetic control of susceptibility
to develop Heymann glomerulonephritis. LEW, AS, BDV, LI
BDV, AS2 and LIAS2 rat strains are highly susceptible,
whereas BN, AVN and DA strains are resistant, even after six
months of observation and administration of additional adju-
vants [84, 85]. These differences may be related either to the
expression of relevant antigens on glomerular epithelial cells or
to the quality and quantity of antibodies. Concerning the latter
issue, it is evident that the activation of autoreactive B cells is
the pivotal event in the pathogenesis of the disease. Investiga-
tions on the cellular mechanisms of antibody production have
been limited to assays with crude brush border fractions and
have shown that the autoantibody response is T cell-dependent
[86—881 and that suppressor T cells are responsible for resis-
tance [89]. More difficult has been to establish whether specific
alterations of T lymphocyte subsets account for different sus-
ceptibility among various strains. Well defined differences have
not been found suggesting that, if present, these alterations
must be of a very subtle nature, possibly related to different
suppressor T cell recruitment by the thymus [90]. Interesting
results were obtained when LEW-1N kidneys were trans-
planted into BN rats. The two strains are RT-1 identical
(RT-l'), but differ in an unknown number of weak histocom-
patibility loci, so that grafts survive without signs of rejection
for at least five months. Membranous glomerulonephritis, char-
acterized by anti-brush border antibodies, develops in the renal
graft but not in BN native kidney. Antibodies eluted from the
graft react with the brush border of LEW-lN kidneys but not
with that of BN rats. In contrast, antibodies eluted from
glomeruli of LEW rats with classical autoimmune Heymann
glomerulonephritis react with the brush border of BN kidney
[911. The experiments show that Hey mann autoantibodies and
alloantibodies have different specificity, and that LEW-1N and
BN kidneys have different susceptibility to develop Heymann
glomerulonephritis. It is unknown whether these differences
depend upon the quality and quantity of antibodies or upon the
expression of relevant antigens at the surface of glomerular
epithelial cells. In conclusion, though antibodies to gp330 are
indispensable for the development of Heymann glomerulone-
phritis, full expression of injury probably requires cooperation
of polyvalent antibodies and multiple antigen-antibody systems
[67, 80, 92].
d. Patho genesis. Immune deposits are the hallmark of im-
mune complex injury and the understanding of their formation
sheds light on the pathogenesis of Heymann glomerulonephri-
tis. Studies have been performed in vitro and in vivo. In vitro it
was observed that after interaction at 37°C of divalent polyclo-
nal antibodies to Fx1A with cultured rat glomerular visceral
epithelial cells, immune complexes are rapidly redistributed at
the cell surface with patching, capping and shedding. Monova-
lent antibodies fail to induce similar results indicating a need for
cross linking. Further, drugs blocking energy production or
inhibiting the cytoskeleton prevent redistribution of immune
complexes at the cell surface. Polyclonal and most remarkably
monoclonal antibody to gp330, recognizing fewer reaction sites,
produce similar but weaker effects [93]. In other studies brush
border antibodies characterized by prevalent gp330 reactivity
convert Heymann antigens from a detergent-soluble, mem-
brane-associated form into an insoluble, actin-associated form
[94] in apparent agreement with other results showing that
antibodies to gp330 mainly induce internalization of immune
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complexes, whereas antibody to podocalyxin and to Fx1A
mainly induce immune complex shedding (Camussi et a!, un-
published observations). Would these data be valid for the
interpretation of the antigen-antibody interaction in vivo the
concept that the subepithelial immune deposits result from
endocytosis, intracellular lysosomal processing and subsequent
secretion into the subepithelial space might be entertained. It
must be kept in mind, however, that cultured cells may change
polarity of secretion and expression of surface antigens. More-
over, in vitro, Fx1A antibodies recognize antigens, such as
podocalyxin and heparan sulphate proteoglycans, at the free
surface of the podocytes. By way of contrast, in vivo subepi-
thelial immune deposits result exclusively from interaction of
circulating antibodies with antigens at the base of the foot
processes, or in other layers of the capillary wall proximal to
the circulation.
Studies of passive Heymann glomerulonephritis only par-
tially confirm the results obtained in vitro. Kerjaschki and
Farquhar [52] and Allegri et al [921 showed that formation of
immune deposits requires polyclonal antibodies to gp330 able to
cross link extensively the antigens expressed at the surface of
epithelial cells. Besides, epitope specificity was recognized as
an important characteristic of nephritogenic antibodies because
not all antibodies to gp330 are able to induce formation of
subepithelial deposits. It was proposed that nephritogenicity
may require reactivity with epitopes normally not expressed in
vivo [67]. Chlorpromazine, a drug that blocks calmodulin and
protein kinase C and decreases plasma membrane fluidity [95],
inhibits shedding of immune complexes and formation of im-
mune deposits. This rapid and potent action was ascribed to the
effect of the drug on the cytoskeleton [961. Important informa-
tion was obtained by Kerjaschki, Miettinen and Farquhar [59]
in studies concerning the initial formation of subepithelial
immune deposits in rats injected with divalent polyclonal anti-
bodies to gp330. After crossing the glomerular basement mem-
brane the antibodies bind to clathrin-coated pits at the base of
the foot processes. The resulting immune complexes are shed
into the lamina rara externa and, after 15 minutes, form
morphologically-recognizable immune deposits which remain in
contact with coated pits. The immune deposits, containing both
gp330 and the heterologous antibody, grow in size presumably
by repeated cycles of immune complex formation and shedding.
In time, both antigen and antibody are demonstrated at some
distance from the ectodomain of gp330 and the immune deposits
are eventually driven by hydrodynamic forces into the area of
the slit diaphragm. Continuous growth probably requires de
novo synthesis of gp330 molecules, transport of gp330 to the
cell surface via secretory vesicles and insertion of gp330 into
the coated pits at the base of the foot processes, The observa-
tion that a coated pit is always in contact with immune deposits
might result from movement of the foot processes along the
outer surface of the basement membrane and represent an
expression of delivery of gp330 to the cell surface. Here gp330
would bind to antibodies present in excess in the immune
deposits which would remain firmly attached to the basement
membrane by a covalent link similar to that induced by free
oxygen radicals [971 or by interaction with the C3b receptors of
laminin [98]. If this interpretation is correct gp330 would behave
like a "secreted" antigen rather than a classical cell surface
receptor and there is indeed evidence that the synthesis of
gp330 is increased in the ergastoplasm of the podocytes when
specific antibody interact with the cell surface [54]. This issue is
germane to the function of the coated pits, generally recognized
as structures specialized in receptor-mediated endocytosis [101.
It is presently unknown whether the coated pits of the po-
docytes in rats genetically susceptible to develop Heymann
glomerulonephritis have some internalization-defective muta-
tion [991. Such an abnormality would be analogous to the
deletion of exons encoding transmembrane and cytoplasmic
domains of LDL receptors. These truncated receptors are
largely secreted, rather than internalized with ligands [1001. In
Heymann glomerulonephritis, however, gp330 interacts with an
antibody, not with a physiologic ligand. A second possibility is
that the coated pits of podocytes may function like those of the
lactating mammary gland, which are involved in a well defined
secretory pathway [101]. A third contention proposes that
gp330 is a ligand physiologically internalized at the level of the
coated pits [59]. In Heymann glomerulonephritis crosslinking
antibodies would promote shedding of the ligand from the
coated pits. This interpretation, however, does not account for
the large amount of gp330 apparently synthesized by the
podocytes [52, 54]. These crucial aspects of the pathogenesis of
Heymann glomerulonephritis will be better understood when
the techniques of molecular biology are brought to bear to
establish the amino acid sequence of the gp330 molecule and to
clarify its function. Thus far, immunohistochemical studies of
passive Heymann glomerulonephritis as accurate as those per-
formed by Kerjaschki, Miettinen and Farquhar [59] have not
been performed with antibodies reactive with other cell surface
antigens of the glomerular capillary wall.
In Heymann glomerulonephritis the formation of immune
deposits does not directly induce tissue injury. Rather, damage
occurs because the complement system is activated [102]. The
demonstration that deposits of rat C9 and complement mem-
brane attack complex neoantigens are present in glomeruli of
rats with Heymann glomerulonephritis suggest that the mem-
brane attack complex (C5b-C9) is directly responsible for
epithelial cell injury and proteinuria [103—105]. This hypothesis
is confirmed by experiments showing that increased protein
excretion and glomerular epithelial cell damage does not occur
when isolated rat kidneys are perfused with Fx1A antibodies
and C8-deficient human plasma or C6-deficient rabbit serum
[106, 1071. Studies performed with cultured glomerular epithe-
hal cells confirm that cell lysis depends on insertion of C5b-C9
into the epithelial plasma membrane. It was also found that
C5b-C9 is inserted at sites different from antibody-binding sites
and that, eventually, it is shed into the supernatant fluid [108],
a reparative process described in other types of nucleated, not
completely lysed, cells [109]. Parallel studies were performed in
renal tissue obtained at sequential intervals of time from rats
with passive Heymann glomerulonephritis. Deposits of C5b-C9
are first detected between the foot processes and the basement
membrane. By day 3 C5b-C9 is internalized into multivesicular
bodies and exocytosed into the urinary space. Concomitantly,
C5b-C9 is detected in degraded form in the urine [110]. These
observations are discussed in greater detail by Salant et al
elsewhere in this issue. gp330 and heterologous IgG are not
seen in the multivesicular bodies, indicating that immune corn-
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plexes and the lytic system of complement follow different
pathways [110]. The observations that in vitro C5b-C9 appears
shed from the cell surface [108], whereas in vivo it is internal-
ized, shows, again, that discrepant results are generated by the
two experimental approaches.
The discovery that the main pathogenetic mechanism of
Heymann glomerulonephritis is an in situ formation of immune
deposits does not completely exclude the possibility that circu-
lating immune complexes contribute to injury. This hypothesis
is based on the reports of immune complexes in the sera of rats
with active Heymann glomerulonephritis [111], and of gp7O-90
in the sera of normal rats [66]. An antibody reactive with a 45
kD glomerular antigen, but not with the brush border, would
have the properties of an anti-idiotypic antibody to Fx1A and
would be generated by immunization with a not defined com-
ponent of the brush border. Such an antibody would have a
pathogenic role in the development of lesions because it is
concentrated in glomeruli of nephritic rats, and appears in the
serum in concomitance with proteinuria [112, 113].
Another remarkable effect of brush border antibodies is their
ability to induce malformations in the offspring when given to
pregnant rats during the organogenetic period [114]. This im-
portant issue has been recently re-examined. It was found that
injection in pregnant rats of a rabbit anti-rat brush border gp340
kD glycoprotein serum induces abnormal embryonic develop-
ment, especially frequent anaphtalmia, fetal retardation and
embryonic death. In vivo the antibodies are bound to the
visceral yolk-sac endodermal cells and the embryonic endo-
derm [115, 116]. Rabbit antiserum to embryonic visceral yolk-
sac brush border exhibits an immunoprecipitin band in the 330
region and, upon injection into rats, induces a classical Hey-
mann glomerulonephritis [116]. Other studies show that the
teratogenic antibodies are reactive with a 280 kD protein
present in intermicrovillar areas, coated pits of proximal tubular
brush border, and epithelial cells of the visceral yolk sac.
Antibodies to gp330 are devoid of similar teratogenic effects.
Since the 280 kD protein is localized in clatrin coated pits it is
possible that alterations of a specific constituent of the receptor-
mediated endocytic system may induce fetal malformations
[117].
e. Heymann-like glomerular injury in other species. The
co-expression of some antigens in tubular and glomerular cells
is not a prerogative of rats susceptible to Heymann nephritis.
The phenomenon occurs in other species. However, only mice
and, to a lesser extent, rabbits co-express antigens relevant to
the formation of glomerular subepithelial immune deposits. In
mice passively immunized with heterologous anti-mouse Fx 1 A
the antibody persists in the glomerular capillary wall for a time
and in amount sufficient to generate a proteinuric autologous
phase [81]. The anti-FxlA serum recognizes the 90 kD dipep-
tidyl peptidase IV diffusely distributed on the plasma membrane
of glomerular epithelial and, in lesser degree, endothelial cells.
The antiserum also reacts with rat gp9O and gp330, binds to the
coated pits of rat glomerular epithelial cells, and induces
Heymann glomerulonephritis in this species [82]. Thus, the
mouse does not express gp330 but, nevertheless, subepithelial
immune deposits develop by interaction of polyclonal antibod-
ies with an antigen apparently not localized in the coated pits
[67].
In the rabbit, monoclonal antibodies to homologous brush
border 100 kD dipeptidyl peptidase IV or endopeptidase bind to
antigens diffusely localized in the plasma membranes of glomer-
ular epithelial cells. When rabbits are injected with these
antibodies transient subepithelial immune deposits are seen
comparable to those present in rats injected with antibodies to
gp7O-90 [67]. Heterologous rabbit Fx1A antiserum produces in
the rabbit transient subepithelial immune deposits and protein-
uria. In contrast, rabbits actively immunized with homologous
brush border preparations develop a tubular immune complex
disease but not glomerulonephritis, indicating that brush border
antibodies do not recognize cross-reactive antigens in glomer-
ular epithelial cells [118]. A different pathogenetic mechanism
of glomerular injury was proposed for rabbits injected with
guinea pig anti-brush border sera. The antibodies would release
antigens from the brush border with consequent "implan-
tation" in glomeruli, with formation of circulating immune
complexes, or both [119]. Dogs seem to be refractory to
Heymann-like nephritis [1201.
2. Lesions mediated by a monoclonal antibody against SGP-
115/107. Monoclonal antibodies are generally, relatively ineffi-
cient in inducing tissue damage. An apparent exception is a
particular mouse monoclonal antibody of the non-complement
fixing IgG1 class (K9/9) directed against a sialo-glycoprotein
with a molecular weight of 115 and 107 kD (SGP-115/l07) [121].
SGP-1 15/107 is found in the surface of epithelial cells of various
organs. K9/9 injected into rats binds to glomerular visceral
epithelial cells and causes morphological changes of these cells
consisting of focal disappearance of the epithelial foot process
system, vacuole formation, microvillous transformation, and
focal retraction of podocytes. In contrast to Heymann nephri-
tis, granular, subepithelial immune deposits are not found in the
glomerular capillary wall in this model. This may be due to the
fact that SGP-115/107 is non-redistributable or, more likely, to
the fact that the monoclonal antibodies provide for insufficient
cross linkage of SGP-1 15/107 [931. Animals that receive K9/9
together with complete Freund's adjuvant develop transient
proteinuria. The need for non-specific stimulation of the im-
mune system may reflect the synergistic participation of cyto-
kines in the induction of this functional abnormality [1211. The
K9/9 associated glomerular pathology appears to be comple-
ment- and leukocyte-independent.
It is remarkable that monoclonal antibodies that share with
K9/9 a reactivity with SGP-1 15/107 but bind to different epi-
topes, fail to generate visceral epithelial cell lesions in vivo
[1221. Thus, this novel model of glomerular injury depends on
the interaction of antibody with a specific epitope of a cell
surface antigen. The model clearly illustrates that it is not just
the antigen specificity, but also the epitope specificity that
determines the biological effect of antibody binding.
Glomerular endothelial cells
I. Lesions mediated by anti-ACE antibodies. Although eas-
ily detected in other vascular beds, routine immunohistological
techniques fail to reveal ACE on the surface of rabbit glomer-
ular endothelial cells [78]. Evidence for the presence of ACE on
glomerular endothelial cells comes from experiments in which
rabbit kidneys were perfused ex vivo with goat anti-ACE
antibodies [78]. The results show a seven times higher glomer-
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ular binding of anti-ACE IgG than of non-immune IgG, and
granular deposits of goat IgG on the glomerular endothelium.
When rabbits are given goat anti-ACE antibodies for four days,
granular deposits of goat IgG are seen on the glomerular
endothelium on day one; from day three to 24 the gradual
development of subepithelial deposits containing goat IgG and
rabbit IgG and C3, and located mainly in the filtration slits, is
observed. The interpretation has been that immune complexes
formed after in vivo binding of specific antibodies with ACE are
shed from the endothelium and then, under the influence of
hydrodynamic forces and possibly the release of vasoactive
substances from the endothelium [1231, relocate at the epithelial
side of the glomerular basement membrane [78].
That circulating ACE-anti-ACE antibody complexes may
contribute to the subepithelial immune deposits in the glomer-
ular capillary wall is suggested by the finding that, when
anti-ACE antibodies are administered to rabbits made protein-
uric by repeated injections of cationic bovine serum albumin
[1241, not only goat IgG and rabbit IgG and C3, but also ACE
can be demonstrated in these deposits [78]. It is reasonable to
propose that, according to classical concepts [125], a local
increase in permeability facilitates the localization of immune
complexes from extrarenal vascular beds, such as of the lung,
richly endowed with ACE.
2. Lesions mediated by transplantation antibodies. It is
beyond the scope of this review to discuss in detail humorally-
mediated kidney transplant rejection, so only a few comments
will be made. Most clinically relevant alloantigens, such as
MHC Class I and II, blood group, and endothelial-monocyte
antigens, can be demonstrated on kidney endothelial cells [126—
128]. Like other surface proteins, transplantation antigens are
under proper conditions subject to antibody-mediated redistri-
bution and endocytosis [6, 7]. Furthermore, their expression is
subject to modulation by cytokines [129, 130].
Transplantation antibodies not only are responsible for hy-
peracute kidney allograft rejection, but are also thought to
participate in the acute and chronic rejection processes. Cross
linkage of transplantation antigens may be an essential first step
in the activation of effector mechanisms, such as the comple-
ment system, or in the release of vasoactive substances, such as
platelet activating factor and arachidonic acid derivatives [131].
Donor-specific alloantibodies administered at the time of
kidney transplantation may enhance rather than shorten graft
survival [132]. The balance between enhancement and rejection
may depend on the class, affinity, and specificity of the trans-
plantation antibodies. In the absence of immunohistological
observation, one can only speculate on a role for antibody-
mediated antigenic modulation in the phenomenon of enhance-
ment.
Mesangial cells
Lesions mediated by anti-thymocyte antibodies. T cell epi-
topes have been shown on the surface of rat mesangial cells
[133—135]. When injected into rats, heterologous anti-thy-
mocyte antibodies bind, together with C3 and late acting
complement components, to the mesangial cells; after four days
the immune reactants are no longer detectable in glomeruli [79,
136, 137]. Within one hour of the binding severe mesangial cell
lesions, including lysis, are observed. In the days that follow
extensive mesangiolysis and endo- and extra-capillary cell
proliferation become apparent. After several months the
mesangial pathology resolves without scar formation. The
antibody-mediated mesangial cell injury is complement-depen-
dent, but neutrophil-independent [136, 137].
This mesangiopathy and Heymann nephritis share a common
pathogenesis: both conditions result from the reaction of anti-
bodies with plasma membrane antigens and both are comple-
ment-dependent. However, in contrast to the mesangiopathy,
in Heymann nephritis persistent immune deposits are formed
and cell lysis is not an obvious feature, although lysis of target
cells does occur in vitro [108]. These differences serve to
emphasize the importance of local circumstances and of the cell
types involved in the eventual outcome of injury similarly
induced at various tissue sites.
Tubular cells
1. Heymann nephritis. Once rats actively immunized with
Fx1A become proteinuric, autoantibodies passing into the
urinary space bind specifically to antigens on the brush border
of proximal tubules [138, 139]. Concomitantly these rats de-
velop lesions of the proximal tubules consisting of swelling and
fragmentation of the brush border with accumulation in tubular
lumina of numerous plasma membrane vesicles, disappearance
of apical vesicles, degenerative changes, and cell proliferation
[139, 140]. Correlating with the eventual decrease in the titer of
circulating anti-brush border antibodies, there is a morpholog-
ical recovery of the proximal tubules, although functional
abnormalities persist [141]. Proof for the cytotoxic action of
anti-brush border antibodies comes from the finding that the
proximal tubular lesions seen in active Heymann nephritis can
be passively transferred with these antibodies [142]. To produce
tubular pathology both antigen cross linking and cytoskeleton
activation are required [1431. However, at variance to what has
been observed for glomerular epithelial cells [102—108], the
damaging effect of Heymann antibodies on proximal tubular
cells appears to be complement-independent [144].
Rats with active Heymann nephritis not only show subepi-
thelial glomerular capillary wall immune deposits, but also
subepithelial proximal tubule immune deposits [138, 139].
These latter deposits, which contain gp330, initially form in
contact with the basal part of the plasma membrane of the
epithelial cells and can be seen between the basal infoldings
[1391. It is conceivable that they result from the local interaction
of antibodies, which have passed the tubular basement mem-
brane from the interstitium, with Heymann antigens sparsely
expressed on the basolateral membrane of proximal tubular
cells. Alternatively, one might propose that antigen-antibody
complexes transported from the apical part are released at the
base of proximal tubular cells. The tubular deposits are only
temporarily present and they disappear in parallel with the
circulating autoantibodies. The contrasting persistence of the
glomerular immune deposits in Heymann nephritis is consistent
with a role for local factors in the turnover and clearance of
immune deposits [145], The mechanism of removal of tubular
immune deposits is not known but may involve their solubili-
zation by local antigen excess or the crossing of small immune
deposit fragments of the tubular basement membrane with
subsequent disposal via renal lymphatics [145, 146].
Brentjens and Andres: Antibody interaction with antigens 961
2. Lesions mediated by anti-ACE antibodies. ACE is ex-
pressed on proximal tubular cells, densely on the apical and,
much less, on the basolateral plasma membrane [1471. Goat
anti-Ace antibodies injected intravenously into rabbits will
leave peritubular capillaries and reach the base of proximal
tubules where they bind to ACE on the basolateral membrane
(Fukatsu et al, unpublished observations). ACE-antibody com-
plexes then appear to be shed in the basolateral compartment,
forming small immune deposits consisting of ACE, goat IgG,
and rabbit C3. The tubular deposits are only transient and they
disappear when anti-ACE antibodies are no longer available.
The extra-vascular location of the immune complex aggregates
might explain the mild or absent inflammatory reaction [148].
In rabbits made proteinuric, anti-ACE antibodies also bind,
together with complement, to the brush border of proximal
tubules. However, unlike Heymann antibodies, anti-ACE anti-
bodies do not inflict significant damage to the apical part of
proximal tubules.
Secreted antigens
Glomerular visceral epithelial cells
Mercuric chloride-induced glomerulonephritis. Mercuric
chloride administration to rabbits or BN rats causes a biphasic
autoantibody-mediated glomerulonephritis [149, 150]. In the
early weeks after the start of injections of mercuric chloride a
linear deposition of IgG along the glomerular basement mem-
brane is seen. Later in the course of the disease the distribution
of IgG assumes a discrete granular pattern and electron dense
deposits are present at the epithelial side of the glomerular
basement membrane. The nephropathy flow has the character-
istics of a membranous nephropathy. Studies of sera reveal
antibodies tolaminin and type IV collagen [151, 152], which are
major components of the glomerular basement membrane.
Antibodies with the same specificity can be eluted from kidneys
with linear as well as from kidneys with granular immune
deposits. The eluates from nephritic kidneys react with antigens
synthesized and secreted by cultured rat glomerular visceral
epithelial cells. The pattern of reaction of the eluted antibodies
is similar to that observed with anti-laminin and anti-type IV
collagen antibodies. Absorption of the eluates with both laminin
and type IV collagen blocks the reactivity with the cultured
cells. Binding of the eluates with the apical surface of the
cultured cells, as is the case with Heymann antibodies, is not
found [152]. These data are consistent with the hypothesis that
prolonged, continuous interaction of antibodies with basement
membrane antigens secreted by visceral epithelial cells may
contribute to the formation of granular immune deposits in the
subepithelial part of the glomerular basement membrane [152].
According to this concept, both phases of mercuric chloride
glomerulonephritis are different expressions of the same under-
lying process. One of the several alternative explanations is that
the granular immune deposits in mercuric chloride nephropathy
are derived from circulating immune complexes [153]. How-
ever, against such an event and in favor of in situ immune
deposit formation is the finding in rabbits and rats treated with
mercuric chloride of granular immune deposits in organs and
structures not especially involved in filtration and generally not
affected by injury resulting from entrapment of circulating
immune complexes [154, 155].
DZB rats receiving mercuric chloride develop membranous
glomerulonephritis, which, unlike in BN rats, does not seem to
be preceded by a phase of linear localization of IgG along the
glomerular basement membrane [156]. In sera and kidney
eluates, only antibodies against laminin can be demonstrated.
By immunoelectron microscopy, the binding of eluted antibod-
ies to normal rat kidney is restricted to the cell membrane of
glomerular and tubular epithelial cells adjacent to the basement
membrane. In this model a pathogenic role is proposed for
autoantibodies against a cell-binding epitope on the laminin
molecule [156].
Several other animal models further support the notion that
antibodies to basement membrane components may be in-
volved in granular immune deposit formation in glomeruli:
anti-laminin and type IV collagen antibodies have been impli-
cated in the immune complex glomerulonephritis associated
with experimental trypanosomiasis in the rat [157, 158]; suben-
dothelial and mesangial immune deposits are generated in mice
actively immunized with purified laminin [159]; and, lastly,
rabbits immunized with autologous basement membrane de-
velop linear as well as granular immune deposits along the
glomerular basement membrane [160].
Tubular cells
1. Lesions mediated by anti-Tamm-Horsfall protein antibod-
ies. Tamm-Horsfall protein is synthesized in renal distal tubules
and excreted in normal urine. It is identical to the immune
suppressive glycoprotein uromodulin and appears to specifi-
cally bind to and regulate the activity of certain cytokines
including IL-l and TNF [161]. Tamm-Horsfall protein is located
at the surface of the luminal and basolateral membrane and in
apical vesicles and the Golgi complex of cells of the thick
ascending limb of the loop of Henle and the distal convoluted
tubule [162—1641. Rats actively or passively immunized with
Tamm-Horsfall protein develop granular deposits composed of
this protein and of rat IgG and C3 in between the basal
infoldings at the epithelial side of the basement membrane of
the thick ascending limb of the loop of Henle [165, 166]. In
immunized mice, similar deposits are also found along distal
convoluted tubules [164]. The presence of circulating antibodies
to Tamm-Horsfall protein is required to prevent a rapid clear-
ance of the tubular immune deposits [145, 146]. There is no
inflammatory reaction following the immune deposit formation
[164, 165]. Inflammation at the base of the ascending thick limb
and scarring are seen in rabbits immunized with Tamm-Horsfall
protein [167], The rabbit model differs from that established in
the rat and mouse in that immunoglobulin deposition is not a
feature [167].
Antibodies to Tamm-Horsfall protein injected into rats arti-
fically made proteinuric bind to the luminal surface of the cells
of the thick ascending limb of the loop of Henle, an event
followed by the appearance of large luminal electron-dense
deposits [168]. Deposits in the lumen of proximal tubules are
not observed in Heymann nephritis [139]. Similar, however, is
the observation of increased mitotic activity in the affected
tubular segments [140, 168]. Antibody reactions with Tamm-
962 Brentjens and Andres: Antibody interaction with antigens
Horsfall protein are discussed more extensively by Wilson
elsewhere in this issue.
2. Tubulointerstitial nephritis in rabbits mediated by auto-
antibodies to a proximal tubular 70 kD antigen. Rabbits receiv-
ing repeated kidney allografts [169] or actively immunized with
homologous glomeruli-free kidney cortex [170, 1711 or homol-
ogous Fx1A [118], reveal extensive peritubular fibrosis and
tubular atrophy together with a mild infiltration of the intersti-
tium with mononuclear leukocytes. Some of the rabbits have
glucosuria and aminoaciduria. Granular deposits of IgG and C3
can be demonstrated at the epithelial side of the basement
membrane of proximal tubules. Glomerular deposits are absent.
The serum and kidney eluates of the animals contain antibodies
reactive in vitro with normal proximal tubular cells. In addition,
these antibodies bind to the granular deposits in diseased
kidneys [172]. Passive transfer of serum of immunized rabbits
to normal rabbits results in focal deposition of IgG along tubular
basement membranes in a pattern identical to that seen in the
donors. Immunoelectron microscopy using eluates of nephritic
kidneys shows the responsible antigen to be located in normal
rabbits on the brush border and apical vesicles of proximal
tubules. The antigen has an apparent molecular weight of 70 kD
(Fukatsu et al, unpublished observations). Observations made
in this rabbit model of tubulointerstitial nephritis led to the
original formulation of the hypothesis that granular immune
deposits in tissues may form by the local reaction of circulating
antibodies "leaking" from or secreted by cells surrounded by
basement membrane [171]. Species differences in epitope rec-
ognition may explain why in rabbits the administration of
heterologous anti-rabbit Fx1A antibodies causes glomerular but
not tubulointerstitial lesions [1181.
Arterial muscle cells
SL/Ni mice spontaneously develop a systemic arteritis that
also involves the kidney [1731. The arteritis is characterized by
segmental fibrinoid necrosis of the vessel wall and dense
perivascular inflammatory cell infiltrates, lesions not unlike
those seen in patients with periarteritis nodosa. Just before or at
the time of onset of the arteritis, budding of a large number of
murine leukemia viral C-type particles from the plasma mem-
brane of muscle cells of the arterial media is observed. The
earliest injury, consisting of degeneration and necrosis of me-
dial muscle cells, may be mediated by the binding of comple-
ment-fixing antibodies to gp7O of the C-type particles on the cell
surfaces [174]. In a later phase of the disease, granular deposits
of immunoglobulins, complement, and viral antigens accumu-
late in the wall of affected arteries. These immune deposits,
presumably derived from circulating immune complexes, may
amplify the arterial injury.
Planted antigens
Lesions mediated by anti-Helix pomatia lectin antibodies
In normal glomeruli, Helix pomatia lectin binds especially to
the glycocalyx of visceral epithelial cells between the base of
the foot processes and the basement membrane [175]. An
increase in glomerular lectin binding sites is observed after
neuraminidase treatment. The increase is striking for the sur-
face of podocytes facing the urinary space and for the surface of
endothelial cells. Rat kidneys first perfused ex vivo with neur-
aminidase and then with Helix pomatia lectin reveal the lectin
exclusively on the glomerular endothelium [1761. In rats given
subsequently an intravenous injection of anti-lectin antibodies,
immune complex aggregates form on the endothelial cell sur-
face. With time, these deposits move from the endothelium to a
subepithelial location [176]. The events are accompanied by
mild proteinuria. These data provide further evidence that
antibody-endothelial cell surface interaction may lead to the
formation of subepithelial immune deposits in the glomerular
capillary wall.
The significance of animal models for human kidney pathology
Despite all the studies in laboratory animals, the understand-
ing of the etiology and pathogenesis of the various human
nephropathies is still very limited. However, concepts derived
from experimental immunopathology at least provide leads
helpful in the search for the origin of the nephropathies affecting
our patients. A case in point is membranous glomerulonephri-
tis, the most frequent cause of nephrotic syndrome in adults.
There is a remarkable similarity between the glomerular abnor-
malities in human membranous glomerulonephritis and those in
Heymann nephritis: in both, non-inflammatory, conditions im-
mune deposits are strictly limited to the subepithelial space and
seem to initiate the same basement membrane changes, which
include the characteristic "spikes". An attractive proposition is
that most if not all forms of human membranous glomerulone-
phritis result from the local binding of autoantibodies with
antigens either intrinsic to or planted on the surface of cells of
the glomerular capillary wall [1, 2]. However, unlike Heymann
nephritis, injury of proximal tubules associated with local
deposits of immunoglobulins is not seen in human membranous
glomerulonephritis. This would suggest that the antigens re-
sponsible for membranous glomerulonephritis in man are not
shared by the glomerular capillary wall and the brush border of
proximal tubules [177—179]. This notion is supported by the
following observations: First, although there are a few descrip-
tions of patients with Heymann-like nephritis in the literature
[180—186], attempts to detect brush border antigens in the
glomerular deposits of human membranous glomerulonephritis
have generally been unsuccessful [187—190]. Second, in normal
human kidneys a plasma membrane protein of 400 kD, cross
reactive with the Heymann antigen gp330, is present on proxi-
mal tubular but not on glomerular epithelial cells [178]. Third,
an effort to induce a Heymann-like nephritis in non-human
primates has failed so far. Monkeys actively or passively
immunized with human FxlA develop a tubular but not a
glomerular immune complex disease [191]. In addition, in vitro
perfusion of normal human kidney with rabbit anti-human brush
border antibodies does not result in glomerular immune depos-
its [191]. Thus it seems unlikely that normal human brush
border expresses antigens relevant for the induction of in situ
immune complex formation in primate glomeruli.
It has been reported that glomerular eluates from patients
with idiopathic glomerulonephritis react with a 90 kD human
renal glycoprotein and bind to glomerular immune deposits in
50 percent of patients with the disease tested [1921. A patho-
genesis similar to that proposed for experimental mercuric
chloride-induced glomerulonephritis [1521 may be considered
for membranous glomerulonephritis occasionally following au-
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toimmune anti-glomerular basement membrane nephritis [1931
or occurring in association with certain drugs [194—198].
One of the many problems encountered in the identification
of the pathogenic antigens in human membranous glomerulone-
phritis is that autoantibodies, presumably present at the onset,
may no longer be in the circulation at the time that patients have
developed clinical symptoms, making serological studies unpro-
ductive. The search for responsible antigens should continue
making use, among other means, of monoclonal antibodies to
defined antigens on human glomerular cells. Intensified studies
of drug-induced or cancer-associated membranous glomerulo-
nephritis, may also prove to be rewarding.
Sera of patients with systemic lupus erythematosus and
kidney eluates of lupus-prone mice [199] contain antibodies
reactive with so-called "lupus associated membrane protein"
(LAMP), which is distributed on the surface of a variety of
cells, including glomerular epithelial cells, LAMP is located in
clathrin coated pits on these latter cells [200]. Interestingly,
LAMP is recognized by a monoclonal antibody to dsDNA.
These data raise the possibility that in addition to deposition of
circulating immune complexes, in situ formation of immune
complexes may account for the subepithelial immune deposits
in the kidneys of patients with lupus membranous glomerulo-
nephritis [200].
Tubular immune deposits are frequently noticed in lupus
nephritis [201]. Their widespread distribution suggests that they
arise from circulating immune complexes rather than from in
situ formed immune complexes. In long functioning human
renal allografts, tubular deposits of immunoglobulins and com-
plement are sometimes found in a pattern reminiscent of that
seen in rabbits receiving multiple renal allografts [169, 202]. The
pathogenesis of these human lesions is unknown.
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